Eva Obermayr

ORCID: 0000-0001-6324-2961 · 6 papers in corpus
2025
Genetic Variants of Interleukin-8 and Interleukin-16 and Their Association with Cervical Cancer Risk.
Life (Basel, Switzerland) ·doi:10.3390/life15020135

BackgroundCervical cancer (CC) is the fourth most common cancer diagnosis in women worldwide. Infection with high-risk human papillomavirus (HPV) is a critical but not determinative condition for CC development, as several co-factors modula…

article 2024
Association of Four Interleukin-8 Polymorphisms (-251 A>T, +781 C>T, +1633 C>T, +2767 A>T) with Ovarian Cancer Risk: Focus on Menopausal Status and Endometriosis-Related Subtypes
Biomedicines ·doi:10.3390/biomedicines12020321

Interleukin-8 (IL-8) is involved in the regulation of inflammatory processes and carcinogenesis. Single-nucleotide polymorphisms (SNPs) within the IL-8 gene have been shown to alter the risks of lung, gastric, or hepatocellular carcinomas. …

other 2024
Association of the Single Nucleotide Polymorphisms rs11556218, rs4778889, rs4072111, and rs1131445 of the Interleukin-16 Gene with Ovarian Cancer
International journal of molecular sciences ·doi:10.3390/ijms251910272

Single nucleotide polymorphisms (SNPs) of the IL-16 gene have been reported to influence the risk of several cancers, but their role in ovarian cancer (OC) has not been studied. Using the restriction fragment length polymorphism (PCR-RFLP) …

2022
Biomarker-Based Models for Preoperative Assessment of Adnexal Mass: A Multicenter Validation Study.
Cancers ·doi:10.3390/cancers14071780

Ovarian cancer (OC) is the most lethal genital malignancy in women. We aimed to develop and validate new proteomic-based models for non-invasive diagnosis of OC. We also compared them to the modified Risk of Ovarian Malignancy Algorithm (RO…

2021
Biomarker-based early detection of epithelial ovarian cancer based on a five-protein signature in patient's plasma - a prospective trial.
BMC cancer ·doi:10.1186/s12885-021-08682-y

BackgroundTrial on five plasma biomarkers (CA125, HE4, OPN, leptin, prolactin) and their possible role in differentiating benign from malignant ovarian tumors.MethodsIn this unicentric prospective trial preoperative blood samples of 43 wome…

2013
A combined blood based gene expression and plasma protein abundance signature for diagnosis of epithelial ovarian cancer--a study of the OVCAD consortium.
BMC cancer ·doi:10.1186/1471-2407-13-178

BackgroundThe immune system is a key player in fighting cancer. Thus, we sought to identify a molecular 'immune response signature' indicating the presence of epithelial ovarian cancer (EOC) and to combine this with a serum protein biomarke…